Published in Mediators Inflamm on January 06, 2016
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med (2001) 17.24
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med (2001) 10.36
International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev (2000) 6.30
Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med (1999) 4.82
Diabetic nephropathy in Type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia (1983) 4.48
Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis (2000) 3.37
End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis (1999) 3.00
Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med (2013) 2.93
Podocyte number predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria. Diabetologia (1999) 2.55
Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int (2004) 2.29
Imaging of the porous ultrastructure of the glomerular epithelial filtration slit. J Am Soc Nephrol (2010) 1.85
miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes. Diabetologia (2013) 1.39
Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem (2000) 1.39
The death ligand TRAIL in diabetic nephropathy. J Am Soc Nephrol (2008) 1.25
Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia (2001) 1.21
ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. Diabetes Care (2003) 1.20
Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy. Biochem Biophys Res Commun (2007) 1.18
Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy. Hypertens Res (2009) 1.00
Molecular and cellular events mediating glomerular podocyte dysfunction and depletion in diabetes mellitus. Front Endocrinol (Lausanne) (2014) 0.98
Cytokine-induced osteoprotegerin expression protects pancreatic beta cells through p38 mitogen-activated protein kinase signalling against cell death. Diabetologia (2007) 0.92
The effects of angiotensin-II receptor blockers on podocyte damage and glomerular apoptosis in a rat model of experimental streptozotocin-induced diabetic nephropathy. Acta Histochem (2011) 0.91
Antiangiogenic treatment diminishes renal injury and dysfunction via regulation of local AKT in early experimental diabetes. PLoS One (2014) 0.88
Insulin resistance and heart injury in rats with insulin resistance or type 2 diabetes mellitus. Acta Cardiol (2010) 0.87
Lycorine suppresses RANKL-induced osteoclastogenesis in vitro and prevents ovariectomy-induced osteoporosis and titanium particle-induced osteolysis in vivo. Sci Rep (2015) 0.87
Receptor activator of NF-kappaB and podocytes: towards a function of a novel receptor-ligand pair in the survival response of podocyte injury. PLoS One (2012) 0.82
Sesquiterpene lactones inhibit advanced oxidation protein product-induced MCP-1 expression in podocytes via an IKK/NF-κB-dependent mechanism. Oxid Med Cell Longev (2015) 0.82
Genome-wide association study reveals a polymorphism in the podocyte receptor RANK for the decline of renal function in coronary patients. PLoS One (2014) 0.81
The osteoprotegerin/tumor necrosis factor related apoptosis-inducing ligand axis in the kidney. Curr Opin Nephrol Hypertens (2014) 0.81
Toll-like receptor activation: from renal inflammation to fibrosis. Kidney Int Suppl (2011) (2014) 0.81
Irbesartan can improve blood lipid and the kidney function of diabetic nephropathy. Discov Med (2015) 0.80
Effects of irbesartan on serum uric acid levels in patients with hypertension and diabetes. Clin Pharmacol (2014) 0.80
Renal protection by low dose irbesartan in diabetic nephropathy is paralleled by a reduction of inflammation, not of endoplasmic reticulum stress. Biochim Biophys Acta (2014) 0.80
Irbesartan ameliorates diabetic nephropathy by reducing the expression of connective tissue growth factor and alpha-smooth-muscle actin in the tubulointerstitium of diabetic rats. Pharmacology (2008) 0.79
Corrigendum to "Irbesartan Ameliorates Diabetic Nephropathy by Suppressing the RANKL-RANK-NF-κB Pathway in Type 2 Diabetic db/db Mice". Mediators Inflamm (2016) 0.75
Metadherin facilitates podocyte apoptosis in diabetic nephropathy. Cell Death Dis (2016) 0.75